TIDMGWP

RNS Number : 0174C

GW Pharmaceuticals PLC

23 June 2016

 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 
 
 
 
 1. Identity of the issuer or                                     GW Pharmaceuticals PLC 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: (ii) 
-----------------------------------------------------------  --------------------------- 
 2 Reason for the notification (please tick the appropriate 
  box or boxes): 
---------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights 
------------------------------------------------------------  -------------------------- 
 An acquisition or disposal of qualifying financial                        X 
  instruments which may result in the acquisition 
  of shares already issued to which voting rights 
  are attached 
------------------------------------------------------------  -------------------------- 
 An acquisition or disposal of instruments with 
  similar economic effect to qualifying financial 
  instruments 
------------------------------------------------------------  -------------------------- 
 An event changing the breakdown of voting rights 
------------------------------------------------------------  -------------------------- 
 Other (please 
  specify): 
----------------------------------------------------------    -------------------------- 
 3. Full name of person(s)                                     Scopia Capital Management 
  subject to the                                                                      LP 
  notification obligation: 
  (iii)                                                          Scopia Management, Inc. 
-----------------------------------------------------------  --------------------------- 
 4. Full name of shareholder(s)                                      Goldman Sachs & Co. 
  (if different from 3.):(iv) 
-----------------------------------------------------------  --------------------------- 
 5. Date of the transaction                                                 20 June 2016 
  and date on 
  which the threshold is 
  crossed or 
  reached: (v) 
-----------------------------------------------------------  --------------------------- 
 6. Date on which issuer                                                    22 June 2016 
  notified: 
-----------------------------------------------------------  --------------------------- 
 7. Threshold(s) that is/are 
  crossed or 
  reached: (vi, vii)                                                                  5% 
-----------------------------------------------------------  --------------------------- 
 
 
 
 8. Notified details: 
-------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares (viii, ix) 
-------------------------------------------------------------------------------------------------------- 
 Class/type      Situation previous              Resulting situation after the 
  of              to the triggering               triggering transaction 
  shares          transaction 
 
  if possible 
  using 
  the ISIN 
  CODE 
--------------  ------------------------------  -------------------------------------------------------- 
                 Number          Number          Number         Number of voting      % of voting 
                 of               of              of shares      rights                rights (x) 
                 Shares           Voting 
                                  Rights 
--------------  --------------  --------------  -------------  --------------------  ------------------- 
                                                 Direct         Direct    Indirect    Direct    Indirect 
                                                                (xi)       (xii) 
--------------    ------------   ------------   -------------  --------  ----------  --------  --------- 
 
 
  Not 
  Applicable 
                --------------  --------------  -------------  --------  ----------  --------  --------- 
 
 
 B: Qualifying Financial Instruments 
-------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
-------------------------------------------------------------------------------------------------------- 
 Type of           Expiration     Exercise/                      Number of voting     % of voting 
 financial          date           Conversion                     rights that          rights 
 instrument         (xiii)         Period (xiv)                   may be 
                                                                  acquired if 
                                                                  the 
                                                                  instrument 
                                                                  is 
                                                                  exercised/ 
                                                                  converted. 
----------------  -------------  -----------------------------  -------------------  ------------------- 
 American 
  Depositary 
  Receipts         Not 
  US36197T1034      Applicable    Not Applicable                 13,802,724           5.25% 
----------------  -------------  -----------------------------  -------------------  ------------------- 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments (xv, xvi) 
-------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
-------------------------------------------------------------------------------------------------------- 
 Type of          Exercise       Expiration     Exercise/       Number of voting      % of voting 
  financial        price         date           Conversion       rights instrument     rights (xix, 
  instrument                     (xvii)         period           refers to             xx) 
                                                (xviii) 
---------------  -------------  -------------  --------------  --------------------  ------------------- 
 Not Applicable                                                                       Nominal   Delta 
---------------  -------------  -------------  --------------  --------------------  --------  --------- 
 
 
 Total (A+B+C) 
-------------------------------------------------------------------------------------------------------- 
 Number of voting rights                          Percentage of voting rights 
-----------------------------------------------  ------------------------------------------------------- 
 13,802,724                                       5.25% 
-----------------------------------------------  ------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable: 
  (xxi) 
---------------------------------------------------------------------------------- 
 
   Scopia Capital Management LP is the investment manager 
   of certain funds that beneficially own the financial 
   instruments disclosed in Section 8 of this form and 
   which controls the voting rights attached those financial 
   instruments. 
 
   Scopia Management, Inc. is the general partner of Scopia 
   Capital Management LP 
 
 Proxy Voting: 
---------------------------------------------------------------------------------- 
 10. Name of the proxy holder:                                      Not Applicable 
---------------------------------------------  ----------------------------------- 
 11. Number of voting rights proxy 
  holder will cease to hold: 
---------------------------------------------  ----------------------------------- 
 12. Date on which proxy holder will 
  cease to hold voting rights: 
---------------------------------------------  ----------------------------------- 
 
 
  13. Additional information: 
-------------------------------------------  ------------------------------------- 
 14. Contact name:                              Samantha Nasello, Chief Compliance 
                                                                           Officer 
-------------------------------------------  ------------------------------------- 
 15. Contact telephone number:                                     +1.212.370.0304 
-------------------------------------------  -------------------------------------

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLEAPKAAESKEFF

(END) Dow Jones Newswires

June 23, 2016 02:30 ET (06:30 GMT)

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.